UNSPSC 51342905: Vidarabine anhydrous

This classification denotes a purine antagonist and antiviral agent with the molecular formula C10H13N5O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3XQD2MEW34, chemically known as vidarabine, anhydrous, but more generally known as vidarabine anhydrous, which bears US NIH Compound Identifier 21704. European Medicines Agency schedules vidarabine anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00047MIG.

Most nations, for tariff purposes, schedule vidarabine anhydrous under HS 29349990. Vidarabine anhydrous bears US NLM identifiers UMLS ID C2700247 and NCI Concept Code C77393. SMILES: C1NC(C2C(N1)N(CN2)[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)N.

UNSPSC 51342905 Vidarabine anhydrous, a Commodity code, represents specialized pharmaceutical products that state and local health agencies procure for treatment and emergency response. Recent state and local opportunities tagged under this code show minimal direct relevance to vidarabine itself — the posted solicitations address doxycycline and ciprofloxacin antibiotics, naloxone, and drug deactivation systems. State and local health departments and counties use cooperative purchasing vehicles such as MMCAP Infuse to streamline pharmaceutical acquisition, often posting piggyback contracts and competitive bids through their procurement portals. Award values on individual pharmaceutical contracts run into the millions of dollars; the Illinois Department of Public Health's award to Chartwell Rx LLC totaled $2,999,999.11 over a three-year term including renewals.

The code shows activity primarily in Illinois and Florida based on recent postings. The Illinois Department of Public Health awarded a pharmaceutical warehouse piggyback contract through MMCAP Infuse to Chartwell Rx LLC on August 28, 2026 (Bid Number 26-482DPH-PREPD-B-53392) for doxycycline and ciprofloxacin tablets under an Invitation for Bid process with a 12-month initial term and renewal options through year three. Seminole County, Florida posted an Invitation for Bid (IFB60459723LAS) on June 30, 2026 for 1,900 units of naloxone and 800 drug deactivation systems annually, with quarterly deliveries required to the Seminole County Community Health Building in Sanford, Florida. The mismatch between the code's stated scope (vidarabine anhydrous, an antiviral agent) and the actual pharmaceutical products in these recent opportunities suggests the code sees limited or mislabeled activity in current state and local procurement.